Now in the RheumNow poster hall:
JAKi safety and efficacy in bDMARD-IR patients with RA. Results from a long-
term extension through Week 204. Sponsored by AbbVie US Medical Affairs.
https://t.co/eoSFQMXmQk https://t.co/DFuC8kOGQp
Links:
Safety and Efficacy of a JAKi in Patients With Rheumatoid Arthritis Refractory …
https://bit.ly/3SIaS77
Feb-02-2024
